The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status
作者： Wolfgang J. Köstler , Thomas Brodowicz , Gernot Hudelist , Margaretha Rudas , Reinhard Horvat
DOI: 10.1007/S00432-005-0670-3
关键词:
摘要: Purpose: Her-2/neu and p53-mediated signalling have been shown to interact at various cellular levels. However, the clinical relevance of p53 alterations in patients receiving trastuzumab for Her-2/neu-overexpressing metastatic breast cancer (MBC) remains unknown. The present study was performed corroborate previous vitro findings from our laboratory showing that induces growth arrest apoptosis a p53-independent manner. Method: Retrospective immunohistochemical (IHC) analysis protein expression carried out on tumour specimens 104 trastuzumab-based treatment MBC single institution. status correlated with response (R) benefit (CB), median progression-free survival (PFS) time overall (OAS) univariate multivariate analyses. Results: Characteristics were similar between p53-negative p53-positive tumours (all P>0.05). In analyses, R (39% vs 26%, P=0.208), CB (70% 57%, P=0.218), PFS (6.2 months 4.2 months, P=0.186) OAS (23.8 23.2 P=0.650) tumours, respectively. not significant predictor R, CB, or Conclusions: status, as determined by IHC, is efficacy MBC.
springer.com
sci-hub.se 参考文章(66)
Flavia Longo, Breast Cancer Conference Tumori. ,vol. 88, pp. 1- 10 ,(2002) , 10.1177/030089160208800523
T Brodowicz, D Kandioler, S Tomek, C Ludwig, M Rudas, R Kunstfeld, W Koestler, M Hejna, A Budinsky, C Wiltschke, C C Zielinski, Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. British Journal of Cancer. ,vol. 85, pp. 1764- 1770 ,(2001) , 10.1054/BJOC.2001.2197
Karlan B, Plummer Sj, Casey G, Ramos Jc, Shaughnessy M, Lopez Me, Arboleda Mj, Slamon Dj, DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. ,vol. 13, pp. 1971- 1981 ,(1996)
Kathy D. Miller, George W. Sledge, Sreenivasa Nattam, Frank Monaco, Rafat Ansari, Gary Gize, Judy Sisk, Kenneth Pennington, Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer Oncology. ,vol. 15, pp. 38- 40 ,(2001)
Binhua P. Zhou, Yong Liao, Weiya Xia, Yiyu Zou, Bill Spohn, Mien-Chie Hung, HER-2 / neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation Nature Cell Biology. ,vol. 3, pp. 973- 982 ,(2001) , 10.1038/NCB1101-973
Weiya Xia, Bill Spohn, Mong-Hong Lee, Mien-Chie Hung, Binhua P. Zhou, Yong Liao, Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature Cell Biology. ,vol. 3, pp. 245- 252 ,(2001) , 10.1038/35060032
T. Mitsudomi, J. D. Minna, J. D. Minna, M. M. Nau, D. S. Liscia, G. R. Merlo, R. J. Osborne, I. Chiba, R. Callahan, T. Takahashi, T. Venesio, A. P M Cappa, Mutations in the p53 gene in primary human breast cancers. Cancer Research. ,vol. 51, pp. 6194- 6198 ,(1991)
Steven Seelig, Carlos L. Arteaga, Walter King, F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter, Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action Cancer Research. ,vol. 62, pp. 4132- 4141 ,(2002)
Bert Vogelstein, David Lane, Arnold J. Levine, Surfing the p53 network Nature. ,vol. 408, pp. 307- 310 ,(2000) , 10.1038/35042675
R Kumar, H M Shepard, J Mendelsohn, Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Molecular and Cellular Biology. ,vol. 11, pp. 979- 986 ,(1991) , 10.1128/MCB.11.2.979